Advancements in dry powder delivery to the lung

被引：49

作者：

Son, Yoen-Ju ^{[1
]}

McConville, Jason T. ^{[1
]}

机构：

[1] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA

来源：

DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY | 2008年 / 34卷 / 09期

关键词：

carrier particles; powder dispersion; passive inhalation devices; mechanical inhalation devices;

D O I：

10.1080/03639040802235902

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The dry powder inhaler (DPI) has become widely known as a very attractive platform for drug delivery. Many patients have traditionally used DPIs to treat asthma and chronic obstructive pulmonary disease. Recently, the development of new DPIs for delivering therapeutic proteins such as insulin has been accelerated by patient demands, and innovative research. The current market for DPIs has over 20 devices presently in use, and many devices under development for delivering a variety of therapeutic agents. DPIs are recognized as suitable alternatives to pressurized metered dose inhalers for some patients, but the performance of DPI devices may vary according to a given patient's physiological condition. This variation can be associated with the necessary powder dispersion mechanism of each device. As such, much interest has focused on the development of efficient powder dispersion mechanisms, as this effectively minimizes the influence of interpatient variability. This article reviews DPI devices currently available, advantages of newly developed devices, outlines some requirements for future device design.

引用

页码：948 / 959

页数：12

共 107 条

[1] Advances in asthma and COPD management:: Delivering CFC-free inhaled therapy using Modulite® technology [J].

Acerbi, D. ;

Brambilla, G. ;

Kottakis, I. .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (03) :290-303

[2]

*AM DIAB ASS, 2003, DIABETES CARE S1, V26, pS121

[3]

Ashurst I, 2000, Pharm Sci Technol Today, V3, P246, DOI 10.1016/S1461-5347(00)00275-3

[4] Inhalation system for pulmonary aerosol drug delivery in rodents using large porous particles [J].

Ben-Jebria, A ;

Eskew, ML ;

Edwards, DA .

AEROSOL SCIENCE AND TECHNOLOGY, 2000, 32 (05) :421-433

[5]

Bindra Sanjit, 2002, Curr Opin Investig Drugs, V3, P758

[6] An in vivo and in vitro comparison of two powder inhalers following storage at hot/humid conditions [J].

Borgström, L ;

Asking, L ;

Lipniunas, P .

JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG, 2005, 18 (03) :304-310

[7] LUNG DEPOSITION OF BUDESONIDE INHALED VIA TURBUHALER(R) - A COMPARISON WITH TERBUTALINE SULFATE IN NORMAL SUBJECTS [J].

BORGSTROM, L ;

BONDESSON, E ;

MOREN, F ;

TROFAST, E ;

NEWMAN, SP .

EUROPEAN RESPIRATORY JOURNAL, 1994, 7 (01) :69-73

[8] Modulation of aerosol clouds produced by pressurised inhalation aerosols [J].

Brambilla, G ;

Ganderton, D ;

Garzia, R ;

Lewis, D ;

Meakin, B ;

Ventura, P .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 186 (01) :53-61

[9] Influence of excipients and storage humidity on the deposition of disodium cromoglycate (DSCG) in the Twin Impinger [J].

Braun, MA ;

Oschmann, R ;

Schmidt, PC .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 135 (1-2) :53-62

[10] Peak inspiratory flow rate and slope of the inhalation profiles in dry powder inhalers [J].

Broeders, MEAC ;

Molema, J ;

Vermue, NA ;

Folgering, HTM .

EUROPEAN RESPIRATORY JOURNAL, 2001, 18 (05) :780-783

← 1 2 3 4 5 6 7 8 9 10 →